Drug
P2Y12 antagonist monotherapy
P2Y12 antagonist monotherapy is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (33.3%)
N/A2 (66.7%)
Trials by Status
completed133%
not_yet_recruiting133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
NCT06763744
completednot_applicable
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
NCT03447379
unknownnot_applicable
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
NCT02079194
Clinical Trials (3)
Showing 3 of 3 trials
NCT06763744Phase 4
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
NCT03447379Not Applicable
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
NCT02079194Not Applicable
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3